Mendus

Press release
Stockholm, Sweden, January 8, 2024

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming industry conferences:

Executive Insights 2024
Stockholm, Sweden, April 9, 2024
CEO Erik Manting will participate in the annual Executive Insights Forum: Drugs and Money in a Time of Change. Executive Insights is a networking event for Swedish executives and investors.
https://executive-insights-2024.confetti.events/

Investing in Oncology Forum
Stockholm, Sweden, April 10, 2024
CEO Erik Manting will present and take part in a panel discussion at the Investing in Oncology Forum 2024 hosted by Cord Communications.
https://financialhearings.com/event/49788

EBMT 2024
Glasgow, Scotland, April 14-17, 2024
CMO Jeroen Rovers will participate in the 50th annual meeting of EBMT, a non-profit medical and scientific organization connecting patients, researchers and other stakeholders to anticipate the future of cellular and stem cell-based therapies.
https://www.ebmt.org/annual-meeting-2024

Van Lanschot Kempen Life Sciences Conference
Amsterdam, The Netherlands, April 16-17, 2024
Mendus management will participate in the annual Van Lanschot Kempen Life Sciences investor conference.
https://www.vanlanschotkempen.com/en-nl/investment-banking/equities/life-sciences-and-healthcare/life-sciences-conference-2024

LSX World Congress 2024
London, April 29-30, 2024
CEO Erik Manting will present and take part in a discussion panel at the 10th annual LSX World Congress which will take place in London.
https://informaconnect.com/lsx-world-congress/biotech-leaders/

For more information, please contact:
Erik Manting, CEO
E-mail: ir@mendus.com

About Mendus AB (publ)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/